Novo Nordisk Partners With OpenAI to Accelerate Drug Development
Danish drugmaker Novo Nordisk said Tuesday it is deploying OpenAI's technology across drug discovery, manufacturing, and business operations as it attempts to regain ground in the weight-loss drug market against competitor Eli Lilly.
The partnership will use OpenAI to analyze datasets, identify drug candidates, and improve manufacturing efficiency and supply chain operations. Novo did not disclose financial terms.
Novo, maker of Wegovy and Ozempic, launched an oral version of Wegovy in January. Lilly won U.S. approval for its weight-loss pill Foundayo this month. Analysts project weight-loss drug revenue will exceed $100 billion annually within a decade.
Pilot Programs Begin This Year
Novo will run pilot programs across research and development, manufacturing, and commercial operations, with full integration planned by the end of 2026. The company said OpenAI will also train its global workforce on AI capabilities.
CEO Mike Doustdar said the goal is to increase productivity rather than cut headcount. "The aim here is not replacing our scientists. It's about supercharging them," he said. The partnership will reduce the need for future hiring growth, though Doustdar said it is not intended to eliminate current roles. Doustdar cut 9,000 jobs after becoming CEO last year.
Drugmakers Turn to AI for Development Tasks
Pharmaceutical companies increasingly use AI to handle routine drug development work, from finding clinical trial participants and selecting trial sites to preparing regulatory filings. Industry executives say AI has not yet delivered on the harder challenge of discovering major new molecules.
Novo said the partnership includes strict data protection, governance, and human oversight, and builds on its existing AI work with other technology partners and research organizations.
Sam Altman, OpenAI CEO, said the collaboration will help Novo "accelerate scientific discovery, run smarter global operations, and redefine the future of patient care."
For IT and development professionals, this partnership demonstrates how generative AI and LLM technologies are being integrated into complex enterprise workflows. Understanding these implementations is increasingly relevant for those building or managing AI for IT and development initiatives in their own organizations.
Your membership also unlocks:
